Theralink Technologies announced that it has significantly expanded the adoption of its Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) precision medicine technology to biopharmaceutical companies, including multinational healthcare corporations. The Company has supported 41 preclinical and clinical studies for 18 biopharma companies and is currently undergoing discussions to develop Companion Diagnostics (CDx) with several of its existing clients. Leveraging its novel phosphoprotein-based assay, Theralink enables biopharma clients to expedite drug development and ultimately shorten time to market, which can potentially save millions of development dollars, by providing invaluable insights into a drug's biological impact.

Theralink supports its partners across the entire drug development continuum from discovery to clinical market with services including: phosphoproteomic profiling in preclinical models and clinical samples, the evaluation of drug target inhibition within laser capture microdissected tumor samples, and interrogation of compensatory feedback mechanisms and pathways after drug target inhibition. In addition, the Company is in early discussions with several biopharma companies for the development of Companion Diagnostics. The development of Companion Diagnostics using Theralink's assays is a potentially large catalyst for Theralink, as well as its biopharma partners, as it is a required test by oncologists to determine a drug's suitability for their cancer patients.